register free | resend password

Relay Medical announces Provisional Patent for POCT CO-oximetry Technology; Launches HemoPalm website in Mandarin

ID: 1556543
recent pressrelease next pressrelease

(businesspress24) - February 27, 2020 - Relay Medical Corp. (Relay or the Company) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, is pleased to announce the filing of a provisional patent entitled Precision Optical Chambers Device, System, and Method of Manufacturing Same, for its HemoPalm-CX Point-of-Care Testing (POCT) CO-Oximetry device.

The patents main claims cover the single-use blood sample cuvette designed to be used with the HemoPalm-CX. The patent describes a precise and inexpensive method for producing an optical cavity for the purpose of making accurate spectrophotometric measurements on samples of human whole blood. The design solves the problem of manufacturing consistent optical chambers with very short path length, within an inexpensive disposable diagnostic cartridge and/or cuvette. The cartridge is designed for manufacturing at high volume, as well as for ease-of-use in point-of-care testing environments. The design features direct coupling to common sample syringes and a tube insert to ensure representative sampling. PR - HP Patent Feb 27-20 FINAL v.3_PRcom.001.jpeg

Fig 1 HemoPalm-CX single-use blood sample cuvettes PR - HP Patent Feb 27-20 FINAL v.3_PRcom.002.jpeg

Fig 2 HemoPalm-CX single-use cuvette and syringe

Relays HemoPalm-CX portable POCT CO-oximeter complements bedside and near-patient blood gas analyzers that do not have CO-OX capabilities. CO-oximetry measurements are crucial in critical care settings such as the Intensive Care Unit, Cardiac Care Unit, Neonatal Intensive Care Unit, Emergency Department and Emergency Medical Services. In addition to providing hemoglobin fractions that are critical to a full understanding of a patients oxygenation status, the accurate total hemoglobin (and calculated hematocrit) can facilitate transfusion decisions, particularly where POCT blood gas instruments only provide unreliable conductimetric hematocrit measurements.

Mass healthcare events, such as the recent coronavirus outbreak, demonstrate the need for new solutions to combat and contain diseases in the world. Point of care-testing platforms, such as HemoPalm, offer critical data immediately to health care workers to help determine the appropriate treatment and care in hospitals and rural clinics.

China offers a large rapidly advancing market, an aging population, a developing health care system and an ability to quickly adopt new healthcare technologies. Relay Medical plans to continue actively exploring opportunities in China for joint-development of medical devices tailored to the Chinese healthcare market. In order to support development activities in China, Relay Medical has released a HemoPalm website in Mandarin ( To view the content in English, please visit the Relay Medical Website at

In early January, Relay Medical announced that Patent No. 201580025752.6, Joint Spectroscopic and Biosensor System for Point-of-Care Testing, was granted in China.

VIDEO: HemoPalm Proof of Principle Prototype Demonstration

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and data science sectors.


W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger(at)

Office: 647-872-9982
Toll-free/Fax: 1-844-247-6633
Email: info(at)
Suite 1600-401 Bay St.
Toronto, Ontario M5H 2Y4

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Companys control. There are no assurances that the commercialization plans for HemoPalm Corp. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management''s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Companys filings with Canadian securities regulators, which filings are available at

More information:

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: irw
print pressrelease  send to a friend  

Date: 02/28/2020 - 07:52
Language: English
News-ID 1556543
Character count: 3622
Firma: Relay Medical Corp.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Wien


Number of hits: 785


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 146

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.